Gyre Therapeutics Inc (STU:L9S)
€ 12.3 0.3 (2.5%) Market Cap: 1.17 Bil Enterprise Value: 1.15 Bil PE Ratio: 0 PB Ratio: 19.89 GF Score: 30/100

Catalyst Biosciences, Inc. - Special Call Transcript

Dec 14, 2020 / 05:00PM GMT
Monique Kosse
LifeSci Advisors, LLC - MD

Good day, and welcome to the Catalyst Biosciences R&D call on systemic complement regulator programs. (Operator Instructions) As a reminder, this webinar is being recorded, and a replay will be made available on the Catalyst Biosciences website following the event.

I'd like to now turn the call over to your host Dr. Nassim Usman, President and Chief Executive Officer of Catalyst Biosciences. Please go ahead, Nassim.

Nassim Usman
Catalyst Biosciences, Inc. - President, CEO & Director

Thank you, Monique, and good morning to everyone who's attending our complement R&D Day today. We're very excited to be rolling out several new programs, which we will discuss in short order. I will go over the agenda. Excuse me. Apologies, we have a little technical issue here. Okay. Yes.

So I will give a brief introduction today about the company and what we're doing from a very high-level view. And then we're very pleased to have Professor Ron Taylor, Professor Emeritus of Biochemistry and Molecular

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot